For many gene therapy applications the effective titre of retroviral vectors is a limiting factor both in vitro and in vivo. Purification and concentration of retrovirus from packaging cell supernatant can overcome this problem. To this end we have investigated a novel procedure which involves complexing retrovirus to a dense and particulate substrate followed by a short low-speed centrifugation. The study reported here uses heat-killed, formaldehyde fixed Staphylococcus aureus (Pansorbin) absorbed to PG13 derived retrovirus. This complex was then used to harvest retrovirus from packaging cell supernatant: centrifugation and washing of
Introduction
Retrovirally mediated gene therapy requires either retroviral packaging cells releasing large numbers of infectious retroviral particles and/or methods for enhancing the efficiency of retrovirus/target cell interactions (and preferably both). Efforts to optimize the effective titre of retroviral vectors have tended to focus upon three strategies.
(1) New vector constructs have been designed that allow for more efficient expression and packaging of retroviral vector RNA. 1, 2 These have been coupled with a new generation of packaging cell lines producing greater numbers of retroviral particles, [3] [4] [5] which may also have wider target cell trophisms 3, 5, 6 and be more resistant to inactivation, either by centrifugation 6 or human complement. 5, 6 (2) Culture conditions for optimum retroviral vector particle production and efficiency of retroviral/target cell interactions have been improved. Retroviral production can be increased by 'ping-pong' of mutually infectible packaging cells, 7 superinfection, 8 culture of target 9 or packaging cells at 32°C, 10 and in some cases this complex allows the retrovirus to be both purified and concentrated. This procedure increases the effective titre of retrovirus by up to 7500-fold after an only 200-fold reduction in volume. The affinity of Pansorbin for retrovirus allows concentration regardless of its encoded genes and makes this protocol applicable to other popular packaging cells and envelope proteins. Possible explanations for the marked increase in titre of concentrated virus and the mechanism governing the complexing of retrovirus to Pansorbin are discussed. Gene Therapy (2000) 7, 914-923.
by the addition of the histone deacetylase inhibitor sodium butyrate. 11 Once secreted into the supernatant the probability of retroviral particles infecting a target cell is increased by incubation with polycations such as polybrene and protamine sulphate, 12, 13 complexing retroviral particles with liposomes or liposomal lipids, 14 flow-through of culture supernatant 15 and lowspeed centrifugation of retroviral particles with their target cells. 9, 10 Target cells can also be made more receptive to infection by culturing them in phosphatedepleted medium, 10 or by the addition of fibronectin and its truncated derivatives. 16 (3) Many of the above methods can be combined with concentrated or purified retrovirus. Reducing the supernatant volume while preserving the retroviral infectibility has been reported following the passage of retroviral supernatant through molecular weight cut-off filters, 9,17-20 lyophilisation 9 and co-precipitation with calcium phosphate. 21 However, such reductions can be accompanied by the concentration of other components that may be inhibitory to infection 22 or toxic to the target cells. 21 Such developments have resulted from the limitations of centrifugation as a method for purification of intact infectious retrovirus. The various versions of the 'classical method' involve ultracentrifugation for up to 16 h at 18 000 g, 23 and appear to work very well. However, the volume of supernatant that can be purified is relatively small, the efficiency of recovery of infectious retrovirus is low, and the method works best with low-titre retrovirus. 23 Other variants still appearing in the literature
In the absence of an optimized retroviral concentration protocol for vectors other than VSV-G pseudotypes one cannot simply increase the number of retroviral particles applied to the target cells by using more supernatant. This is due to the balance between a retroviral vector half-life of 5-7 h at 37°C and the probability of it coming into contact with a cell target during that period. A retroviral particle travelling by Brownian motion alone is unlikely to travel more than 600 m in one half-life. 28 Thus in a static culture of 1 ml as much as 90% of the retrovirus may be unavailable for infection. Since target cell availability is finite, one cannot use a sufficiently large number of cells in order to interact efficiently with all the available retrovirus.
To utilize fully the 90% of the retrovirus unlikely to contact the cells we have designed a protocol that uses a cheap, readily available, particulate and dense substrate. Retrovirus in packaging cell supernatant mixed with excess substrate forms retroviral/substrate complexes that are dense enough to settle under gravity in static culture within the half-life of the virus. Such complexes can also be subjected to short-term low-speed centrifugation as a novel method of retroviral concentration. Using this substrate the virus remains infectious, does not require special treatment to facilitate its release and the non-toxic substrate can remain in culture long enough to allow for optimal retrovirus/target cell interaction.
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Results
Incubation of PG13 supernatant with formalin fixed Staphylococcus aureus (Pansorbin) For gene therapeutic purposes we have been using the murine fibroblast-derived PG13 packaging cells pseudotyped with the gibbon ape leukaemia virus (GaLv) envelope protein.
3 A mixed population of these cells producing a MoMLV-based vector (pWZLIL2/B7M Fusagene, 30 conferring resistance to Blasticidin S Hydrochloride and subsequently referred to as IL-2/B7) was titred on K562 cells using a soft agar colony counting assay. A representative example of the titre obtained (1.95 × 10 4 c.f.u./ml) from this mixed population can be seen in Figure 1 (T = 0, Control). Although this titre is a substantial improvement on previous packaging cells this is still not efficient enough for our purposes.
We thus decided to test a hypothesis that since both GaLv pseudotype 31 retrovirus and Staphylococcus aureus 32, 33 are know to adhere to fibronectin then retrovirus associated with a relatively large and dense bacteria Gene Therapy may then be able to settle under gravity in culture and increase the localized concentration of retrovirus capable of infecting target K562 cells. A readily available source of cell culture compatible Staphylococcus aureus is heatkilled and formaldehyde fixed but still retains functional Protein A on its surface 34 and may thus retain other surface expressed protein activities. Figure 1 shows an experiment using PG13-derived IL-2/B7 retroviral supernatant preincubated with Pansorbin. In the absence of Pansorbin the freshly harvested supernatant has a c.f.u./ml titre on K562 cells of 1.95 × 10 4 ± 4 × 10 3 c.f.u./ml (T = 0, Control). After 2 h (T = 2, Control) incubation at 4°C in the absence of Pansorbin the c.f.u./ml is unchanged at 1.75 × 10 4 ± 4 × 10 3 c.f.u./ml. However, the presence of Pansorbin in the preincubation has a dose-dependent effect on the c.f.u./ml titre of the retrovirus. Thus up to 25 l of Pansorbin preincubated for 2 h with a PG13-derived retroviral vector incubation increases the effective c.f.u./ml titre on K562 cells by as much as three-fold.
The effect of Pansorbin/retrovirus preincubation duration on infectivity Using 25 l of Pansorbin/5 ml retroviral supernatant the optimum length of preincubation was investigated ( in Figure 1 using 25 l of Pansorbin was three-fold and under the same conditions in Figure 2 it was more than seven-fold. This is consistent with other experiments (data not shown) and an average for this type of experiment is approximately a five-fold c.f.u./ml enhancement.
Low speed centrifugal concentration of retrovirus after complexing with Pansorbin
The experiments described in Figures 1 and 2 were performed on small volumes of supernatant, but in order to be a practical method scaling up is required. The Pansorbin-specific settling of retrovirus under gravity alone suggested that low-speed centrifugation may allow concentration and purification of retrovirus from packaging cell supernatant. We thus incubated 50 ml samples of retroviral supernatant with 250 l of Pansorbin and attempted to concentrate the retrovirus. Figure 3 shows the results of a typical experiment.
The control titre before incubation is roughly equivalent to the analogous titre in Figures 1 and 2 
(T = 0). The bulk of the supernatant was then divided into 50 ml aliquots and incubated for 3 h at 4°C with either no further addition (T = 3), 250 l Pansorbin alone (P) or 250 l of Sansorbin (S). Serial dilutions of samples from T = 3 and P were then used to infect K562 cells. In addition, 5 ml aliquots of T = 3 and P were subjected to further 0.45 m filtration and used for infection (2nd Filter and P Filter). All samples were then centrifugally concentrated and the aspirated supernatant from T = 3, and P used for titration (Contdep and Pdep). The residual supernatant in T = 3 was mixed thoroughly (as if to resuspend a pellet) and then used for titration (Contconc). The remaining Pansorbin and Sansorbin sample pellets were resuspended in 10 ml of fresh medium, centrifuged once again, resuspended in a minimal volume of medium (180-fold reduction on starting volume) and taken for infection (Pconc and Sconc). Each value represents the mean and standard deviation of triplicate colony counts.
can be removed from the co-incubation by filtration alone. Low-speed centrifugation of the remaining 45 ml of Pansorbin retrovirus mix, washing once, and resuspending in 250 l of fresh medium (180-fold volume reduction) before titration results in a c.f.u./ml of 1.1 × 10 8 c.f.u./ml (Pconc), representing an increase in c.f.u./ml of 7.8 × 10 3 -fold. The effective titre detected in the concentrate is substantially higher than one might expect when compared with the control supernatant alone. This anomaly is less striking when the concentrate is compared with supernatant incubated with Pansorbin and titred without centrifugation (Pconc, 1.1 × 10 8 c.f.u./ml : P, 2.3 × 10 5 c.f.u./ml), although we still get a 473-fold increase in titre for only an 180-fold reduction in volume. An infection titration performed with the top 25 ml of the supernatant from the centrifuged samples (Pdep) demonstrates that not all the retroviral infectivity has pelleted alongside the Pansorbin, there still remains a titre in the supernatant of 2.7 × 10 4 c.f.u./ml. This may represent retrovirus that did not bind to the Pansorbin, or retrovirus associated with Pansorbin that did not pellet under low-speed centrifugation.
As a control, centrifugation of retroviral supernatant was also performed after 3 h incubation in the absence of Pansorbin. The invisible pellet was resuspended in 250 l of slurry without a wash step (Contconc), and revealed a surprisingly high titre of 1.6 × 10 6 c.f.u./ml; an enhancement of 115-fold compared with the control, although Ͼ60-fold less than that achieved with Pansorbin alone. Theoretically, a recovery between 68 and 123%
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(depending on comparison with either T = 0 or T = 3 as the control) of retrovirus should not be possible under these conditions, as a 2600 g for 10 min is vastly less than any other centrifugation protocol both in terms of duration and g force.
In order to exclude the possibility that the extracellular Ig-like domains of B7-1 35 may be represented on the surface of the retrovirus 36, 37 and bind to the Pansorbin protein A, the concentration was performed in parallel using Sansorbin (protein A negative Staphylococcus aureus, Wood 46). The retrovirus could still be concentrated to 1.15 × 10 7 c.f.u./ml using Sansorbin although this represents a 10-fold lower efficiency (also seen in Sansorbin without centrifugation) than that achieved with Pansorbin, but still better than centrifugation alone. This would indicate that the protein A component of the Pansorbin concentration may make a major contribution to the concentration effect. However, it is also possible that the Sansorbin (Wood 46) expresses protein A at a level that is normally undetectable, or that Wood 46 has a lower affinity for fibronectin.
Retroviral concentration is not target cell specific
To demonstrate that this effect was not specific to K562 cells alone, the same retroviral preparation was used in parallel to infect two other human myeloid cell lines, NB4 and U937. These are shown in Figure 4 alongside a separate retroviral preparation used to infect human adherent epithelial HeLa cells. The titre of the control 3 h incubation of the retroviral supernatant is extremely low on NB4 cells (46 ± 40.4) with a huge standard deviation: this was determined using 100 l of neat supernatant diluted in 1 ml of cell suspension. After a reduction in volume of 180-fold, the effective titre was increased to 1.3 × 10 4 c.f.u./ml representing an increased titre of only 282-fold.
U937 cells did not infect at all using 100 l of neat supernatant diluted in 1 ml of cell suspension, thus ident-
Figure 4 Pansorbin-mediated retroviral titre enhancement is not only effective on K562 cells. Retroviral supernatant derived from PG13 IL-2/B7 was harvested, divided into 50 ml aliquots and incubated at 4°C with either no further addition (T = 3), or 250 l of Pansorbin. After 3 h samples from all conditions were used to infect NB4, U937 and HeLa cells (T = 3). The remaining volume of each Pansorbin/retrovirus sample was centrifugally concentrated as described and once again used to infect NB4, U937 and HeLa cells (Pconc). Each value represents the mean and standard deviation of triplicate colony counts.
Gene Therapy ical PG13-derived supernatant having a titre of 7.2 × 10 3 c.f.u./ml on K562 cells (Figure 3 ) is reduced by 150-fold on NB4 cells and to zero on U937 cells. Reliable infection of U937 cells is only achieved after concentration (Pconc, 1.3 × 10 3 c.f.u./ml) and since the initial titre was zero no effectiveness of concentration can be estimated. Finally, for HeLa cells, the initial titre of retroviral supernatant of 410 ± 46 is increased more than 4 × 10 3 -fold after a 160-fold concentration (Pconc, 1.65 × 10 6 c.f.u./ml). Although the initial titre of the virus (in the case of K562, NB4 and U937 the same viral preparation on the same day) can vary hugely, the titre is increased in all cases by incubation and centrifugation with Pansorbin, however not particularly effectively in the case of NB4.
Retroviral concentration is not vector insert specific
Having shown that concentration of retrovirus was effective (although variably) on other cell targets, we sought to determine whether the retroviral conjugation with Pansorbin was an effect limited to a specific insert in the retroviral vector (ie B7-1), or applicable to other retroviral vectors shed from PG13. We extended the study to investigate the same retroviral vector spine (pWZLblast 38 ) as the pWZLIL2/B7M Fusagene, 30 but with an alternative insert. This vector encodes a truncated gene with no signal peptide and is referred to as RaRT (truncated retinoic acid receptor ␣). Figure 5 shows that this mixed population of PG13 producer cells sheds retrovirus that can be concentrated in an identical fashion. Titration on K562 cells immediately after filtration showed a titre of 1.25 × 10 5 c.f.u./ml (roughly 10-fold higher than IL-2/B7). Pansorbin-mediated centrifugal concentration elevated this titre to 7.7 × 10 8 c.f.u./ml (Pconc, 6333-fold increase) after a 200-fold reduction in volume. The control retroviral concentration with centrifugation (and washing) demonstrated a 50-fold increase in titre (6.6 × 10 6 ± 8.6 × 10 5 c.f.u./ml), for a reduction in volume of 200-fold (data not plotted).
The same concentrated retroviral preparation again shows a limited (875-fold) increase in titre when used to 
Discussion
This report details a pilot study of a new method for the concentration of retrovirus. The use of Pansorbin as the insoluble dense substrate is a proof of principle that such particles supplied at high density would be able to interact with relatively low-titre retroviral supernatant within the lifetime of infectious retrovirus. In Figure 1 we show that the co-incubation of retroviral supernatant with Pansorbin can enhance the effective titre (in c.f.u./ml) of retrovirus. Examination of the time-course of this interaction ( Figure 2) shows that although the initial interaction is quite rapid, best results were achieved after more that 60 min incubation. We interpret these results as demonstrating that the retrovirus becomes complexed with the Pansorbin, a percentage of which can then settle under gravity in a static culture and increase the local concentration of retrovirus associated with the target cells. It is also apparent that the exposure of K562 cells to Pansorbin The efficiency of Pansorbin-mediated concentration varies with packaging cell type. Retroviral supernatant derived from GP+envAM12IL-2/B7, PA317IL-2/B7, FLYRD18pBabe.puro, FLYA13pBabe.puro and GP+E-86Babe.puro was harvested and immediately titred (Control) on either human K562 or murine 32Dp210 myeloid cells. The remaining samples were divided into either 50 ml (FLYRD18, FLYA13 and GP+E-86) or 10 ml (GP+envAM12 and PA317) aliquotes and incubated at 4°C with either 250 l or 50 l Pansorbin. After 3 h samples were centrifugally concentrated as described and once again used to infect target cells (Pansorbin concentrate). Each value represents the mean and standard deviation of triplicate colony counts.
is not toxic, despite the overnight incubation. It could be argued that rather than promoting infection, the Pansorbin was chelating some inhibitory factor that may be in the supernatant. 8, 22 We think this explanation unlikely as the addition of supernatant from non-infected PG13 producer cells does not inhibit the effective titre of retrovirus in a standard infection protocol (data not shown), and filtration of retrovirus/Pansorbin coincubate indicated the c.f.u. activity separating with the Pansorbin. It is also clear that retrovirus does not need to be dissociated from the Pansorbin for it to be infectious, or that overnight culture at 37°C alone is enough to promote its release. However, this may not be the case in other procedures using Pansorbin and anti-retroviral envelope antibodies for mediating complex formation, in this case infectivity of the retrovirus appears to be compromised. 42 Using data represented in Figures 1 and 2 a rational choice of Pansorbin volume and co-incubation time was chosen and used both in scale up experiments and centrifugal concentration. Pansorbin/retroviral interactions are sufficiently strong in our protocol to allow two rounds of centrifugation at 2600 g, and relatively vigorous resuspension in fresh medium before titration. The combination of the reduced volume and the increased infectivity mediated by gravity in static culture may be one explanation for the fact that increases in titre assayed on K562 are far above that expected by reduced volume alone. It is also possible that some target cells may have an affinity for Pansorbin that can retain retrovirus in the vicinity of the target cell. Figure 3 shows that, whatever the mechanism, the effective titre can be increased by up to 7500-fold for a volume reduction of only 180-fold. It was an additional surprise that centrifugation of the supernatant in the absence of Pansorbin was also capable of increasing the titre, although much less efficiently. This may indicate that PG13-derived retrovirus can become complexed with an unknown factor in culture resulting in cross-linking and the condensation of a centrifugable precipitate.
The depletion study in Figure 3 (Pdep) was not clear. We interpret the activity of the supernatant to indicate that at these speeds the Pansorbin is not fully pelleted. A clearer picture emerged in those samples where the complexed retrovirus was passed through a 0.45 m filter, reducing the titre from that of the pre-filter by as much as 90% (P: PFilter). Once again, however, the titre did not drop to zero, which may indicate that much of the available retrovirus remains unbound to the Pansorbin (even with an optimized protocol) or that the filtration is sufficient to dissociate the bound retrovirus from the Pansorbin.
In the absence of a negative control for the concentration protocol (ideally Pansorbin with no retroviral binding activity) we cannot discount the activity of the protein A on the Pansorbin. Parallel experiments with Sansorbin show that the effect may be quite complex, although the Sansorbin is far less effective than its protein A positive counterpart it still gives quite encouraging results. Sansorbin (Wood 46 strain) is not a genetically engineered substrain of Cowan I (Pansorbin) lacking only protein A, but a completely different strain, thus it may be that quite different cell surface proteins may also be lacking in these cells. Attempts to reproduce the concentration with streptavidin-conjugated paramagnetic beads complexed with a biotinylated protein A purified from a secreting variant Staphylococcus aureus strain showed little or no retroviral binding activity (data not shown), which may help to discount protein A as a ligand.
To determine how widespread the application of this concentration methodology may be, we wished to determine whether K562 is a unique target cell for this type of procedure. Figure 4 shows quite clearly that adherent HeLa cells respond in much the same way but to a lesser extent than K562 cells. The low titre of the IL-2/B7 retrovirus infectivity of U937 cells also meant that no estimate of the ratio of concentration could be made in these cells.
Although the ability of concentrated virus to infect cell lines was not cell specific it was important to determine whether the tropism of the retrovirus for the Pansorbin was unique to the IL-2/B7 insert. We thus repeated the protocol with other vectors, such as the RaRT insert in pWZLblast. Results detailed in Figure 5 show that the ability to concentrate retroviral vectors is not specific to a given insert/vector construct. However, it is interesting to note that in this case the U937 target cells are more receptive to infection than the NB4 cells. This may be due to an insert effect such as the expression of IL-2 being toxic to the U937 cells, although we have been unable to show any inhibition in soft agar cloning efficiency in the three suspension cells with single additions of human IL-2 at concentrations as high as 50 000 U/ml. The cloning efficiency of U937, K562 and NB4 was 78%, 43% and 10%, respectively, in the presence or absence of IL-2 (cells plated at 200 cells per dish; data not shown). Thus, externally applied IL-2 is not toxic to these cells, but regulated expression vectors will be required in order to determine if the presence of de novo intracellular IL-2 is differentially toxic to these cells.
Concentration by Pansorbin centrifugation is performed routinely on 50 ml samples of supernatant, and scaling up this protocol is primarily dependent on the amount of supernatant that can be input into the system. One can centrifuge 400 ml of supernatant every 10 min using 50 ml centrifuge tubes, making the production of virus from litres of supernatant relatively easy. This study was initially performed in response to a problem with low titres of virus and it is interesting to speculate on what could be achieved with high-titre starting material. Pansorbin is purchased as a 10% (w/v) suspension, but an estimate of the number of particles can be obtained by haemocytometer counting and indicates that Gene Therapy the concentration is between 1 × 10 10 and 1 × 10 11 /ml. Thus the standard protocol for concentration of 50 ml of supernatant (250 l Pansorbin) will use around 1.25 × 10 10 particles, and even assuming that each particle can bind only one infectious retrovirus particle this gives a carrying capacity of Pansorbin of 1.25 × 10 10 retroviral particles in 50 ml supernatant. It is probable that this method may be equally or more efficient with high-titre producer cells than with the ones we have studied. Assuming a supernatant contains 1 × 10 6 c.f.u./ml of retrovirus, when mixed with the normal concentration of Pansorbin (2.5 × 10 8 /ml) each retrovirus would be an average of 100 m from its neighbour and the Pansorbin particles only an average of 16 m apart. Thus the retrovirus need only travel 10-20 m before arriving in the proximity of a Pansorbin particle, therefore increasing or reducing the retrovirus content of the supernatant (providing it is below the carrying capacity of the Pansorbin) would make little difference to the probability of the retrovirus contacting a Pansorbin particle. One might expect that the retrovirus would be unable to infect target cells when bound to Pansorbin, and we might presume that when diluted with the target cells at 37°C there may be a back reaction releasing retrovirus gradually into the medium. However, it may also be the case that the retrovirus remains complexed to the Pansorbin while infecting the target cells. We have not as yet investigated methods of retroviral release for this protocol.
At present, we have no definitive data regarding the mechanism for binding, although we are confident that the virus is bound to the Pansorbin, otherwise filtration of co-incubated supernatant would not reduce titre as seen in Figure 3 (P and PFilter). One clue to the mechanism could be obtained by examining different packaging cell lines. In summary, this method appears to work best for the PG13 cells for which the concentration procedure was optimized. Using an identical protocol for targeting K562 cells, we find that Pansorbin alone works well for GP+envAM12 39 and PA317 40 (mouse packaging cells, amphotropic murine leukemia virus envelope), with an increase in titre of 1500-and 600-fold, respectively, when normalized to a 200-fold reduction in volume. This is less efficient with FLYA13 5 (human HT1080 fibrosarcoma cells, amphotropic murine leukemia virus envelope) and very poor with FLYRD18 5 (HT1080 with RD114 feline endogenous virus envelope), respectively 100-and 10-fold increase in titre normalised to 200-fold volume reduction. In addition, we find that retrovirus from ecotropic packaging cells GP+E-86 41 (MoMLV env) titred on murine 32Dp210 43 myeloid cells can be Pansorbin concentrated by 150-fold for a 200-fold reduction in volume, an efficiency in line with FLYA13 on K562 cells.
We think that binding of retrovirus to Pansorbin may be mediated by a fibronectin intermediary. There are at least two bacterial genes, whose protein products appear to be specialized membrane-bound fibronectin binding proteins (fnbA 32 and fnbB 33 ), both of which were cloned from Staphylococcus aureus (although not Cowan I strain). However, the fibronectin binding ability of Cowan I can be blocked by the exogenous application of short recombinant fnbB peptides 33 (fnbA not tested). Although the Wood 46 strain has not been directly tested in this way, it has been demonstrated that the ability of Cowan I to aggregate in the presence of either fibronectin or laminin is essentially absent in Wood 46. 44 It is also of interest that both these strains adhere identically to fibronectincoated tissue culture plasticware 44 indicating that Wood 46 may be deficient in either fnbA or fnbB but probably not both. It has also been reported that retrovirus derived from packaging cell lines GP+E-86, GP+envAM12, PA317 and PG13 all bind a recombinant fragment of human fibronectin (CH-296, 16 ,31 otherwise known as RetroNectin). It is not unreasonable to speculate that retrovirus and fibronectin produced from NIH3T3-derived packaging cells 45 can become bound to fibronectin in the course of culture, and such fibronectin/retrovirus complexes may then bind Pansorbin via fnbA or fnbB. The level of expression of fibronectin from most packaging cells must be a limiting factor in the determination of retroviral titre otherwise no enhancement would be observed after RetroNectin treatment. It is thus of interest that although the murine packaging cells have not been formally tested for the secretion of fibronectin, the human HT1080 fibrosarcoma cells at the core of FLYA13 and FLYRD18 express only 0.004% of total protein as fibronectin compared with the 0.3% associated with normal human diploid fibroblasts, 46 and the FLYRD18 envelope may not even bind fibronectin. 47 The FLYA13 cells, despite utilizing the same env protein as both GP+envAM12 and PA317, also perform rather poorly in concentration assays. Pansorbin/fibronectin/retrovirus complexes may also promote infection in a way analogous to RetroNectin, in that cell binding domains in fibronectin may crosslink to the target cells; 16 this may be less effective in NB4 cells since much of the VLA-4 and VLA-5 they express may be inactive. 48 We have used four different batches of Pansorbin, two of Sansorbin and one batch of Pansorbin equivalent from Sigma Aldrich (Poole, UK). While we observed batch variability of two-to four-fold in the concentrating ability of Pansorbin (2000-to 7500-fold increase in titre after concentration), we find it is always more efficient than Sansorbin, which is in turn always better than the Sigma Aldrich product. At first sight such batch variations are worrying, but the methods of preparation of Cowan I have been optimized and quality controlled on the basis of protein A and not fnb. The poor activity of the Sigma Aldrich product appears to be related to how well it pellets at 2600 g, thus optimizing for better centrifugation may improve its activity.
Although this technique will be useful for in vitro studies, the applicability for therapy is debatable as even in vitro transduced cells will have to spend time in the presence of high concentrations of Pansorbin. Toxic factors may leach off Pansorbin in the course of infection, and these may be toxic in vivo if they become adhered to a cell vaccine. This was speculated upon, and dismissed, as a problem in extracorporeal plasma immunoadsorption using heat-killed, fixed Staphylococcus aureus (Cowan I), 49 even so, only a modified procedure using the Fc binding protein A alone is licensed for humans (management of autoimmune thromobocytopenia purpura, ITPP). 50 Following promising results in virus-induced rat malignancy 51 extracorporeal adsorption of patient plasma using only protein A has reached the stage of clinical trials for metastatic breast cancer, 52, 53 Kaposi's sarcoma 53 and colon carcinoma 53 on the basis of removal of antibody complexes thought to inhibit antitumour immune responses. 52, 53 It is, however, tempting to speculate on the relative contributions of the protein A and fnb on Cowan I in treatment of other malignancies where evidence for the role of retrovirus is more compelling and reduction in viremia would be dependent upon circulating retroviral/antibody complexes. 54, 55 The effect of Pansorbin demonstrates that interactions between retrovirus and a particulate substrate can take place within the half-life of the retrovirus. This has allowed us to develop a simple procedure for the concentration of retroviral vectors. We are now modifying the procedure with the intention of using reagents more conducive to clinical practice and applicable to a wide range of packaging cell lines.
Materials and methods
Cell lines
Human (NB4, U937, K562) and mouse (32Dp210 43 ) myeloid cells lines and HeLa epithelial cells were grown routinely in RPMI + 10% FCS, 2 mm l-glutamine, 100 g/ml streptomycin and 100 U/ml penicillin (all Sigma, Poole, UK Generation and culture of producer cells PG13, GP+envAM12 and PA317 packaging cells were trypsinized and plated at 1 × 10 6 /90 mm dish; after 4 h the medium was aspirated and replaced with 10 ml of filtered (0.45 m) GP+E-86 supernatant containing 4 g/ml polybrene. These calcium phosphate transfected GP+E-86 mixed cell populations produced pWZLIL-2/B7 30 or pWZLRaRT retroviral vectors (conferring resistance to Blasticidin S) or pBabe.puro vectors (conferring resistance to Puromycin). This infection was repeated after 24 h, the cells cultured for a further 48 h and the cells selected in DMEM + 10% FCS containing 10 g/ml Blasticidin S or 5 g/ml Puromycin as appropriate for 4 weeks and a mixed population of resistant cells cryopreserved.
FLYRD18 and FLYA13 packaging cells were initiated at 7.5 × 10 5 /90 mm dish, after overnight culture the medium was aspirated and replaced with 10 ml of filtered (0.45 m) PG13.pBabe.puro supernatant containing 8 g/ml polybrene. After 72 h the medium was aspirated and replaced with fresh medium containing 5 g/ml Puromycin. Cells were culture for a further 7 days at which point all control cultures were dead and the mixed population of survivors cryopreserved.
Generation of retrovirus PG13, GP+envAM12, PA317 and GP+E-86 producer cells were trypsinized and plated at 1 × 10 6 /90 mm dish, after 72 h the medium was replaced; 24 h later the medium was aspirated and filtered through a 0.45 m filter and taken for further processing. FLYA13 and FLYRD18 cells plated at 2 × 10 6 /90 mm dish, after 48 and 72 h the medium was replaced, and after a total of 96 h later the medium was aspirated and filtered through a 0.45 m filter and taken for further processing.
Preparation of Staphylococcus aureus
Pansorbin, Sansorbin or insoluble protein A was diluted 1:20 in RPMI + 10% FCS and stored at 4°C for 18 h. The required amount was centrifuged (2600 g, 20 min, 4°C) and resuspended to the desired concentration in RPMI + 10% FCS.
Preparation and concentration of Pansorbin/ Sansorbin:retrovirus complexes The indicated volumes of Pansorbin/Sansorbin were added to the desired volume of retroviral supernatant in sterile polypropylene tubes and the mix incubated at 4°C under constant motion (Stuart Scientific SRT1 tilting roller mixer (Redhill, UK)). At the indicated times the mix was either taken directly for the determination of c.f.u./ml titre or concentrated by centrifugation. For concentration: 45 or 50 ml of mix were centrifuged (2600 g, 10 min, 4°C), the supernatant discarded, the pellet resuspended in 10 ml of cold DMEM + 10% FCS and centrifuged once again as above. The supernatant was poured off and the tubes stored inverted for 60 s to drain and the pellet resuspended in approximately 250 l of cold RPMI + 10% FCS. Resuspending the pellet can be difficult as it tends to clump (especially Pansorbin), and 250 l final volume tends to be composed of 50% packed volume and slurry and 50% fresh medium. If necessary the mixture can be pulsed at 150 g (to allow efficient recovery) and removed to polypropylene cryovials for storage on ice and determination of c.f.u./ml titre.
Determination of c.f.u./ml titre Suspensions of K562, U937, NB4 and 32Dp210 cells were counted and adjusted to 4 × 10 5 /ml in RPMI + 10% FCS Gene Therapy with polybrene at 4.4 g/ml. The cells were then plated in 24-well cell culture plates in aliquots of 1 ml and incubated at 37°C/5% CO 2 for 1-3 h. Retroviral preparations were serially diluted 1:10 in RPMI + 10% FCS, 100 l added to triplicate wells and mixed thoroughly. After 18-24 h 0.9 ml of cells was mixed with 3.8 ml of RPMI + 24% FCS + 1.3 mm sodium pyruvate and maintained at 37°C followed by an additional 0.3 ml of autoclaved 5% w/v Noble Agar in water (final concentration 0.3%) which had been maintained at 60°C. The cells were then plated in 60 mm tissue culture dishes and, after allowing the agar to set, placed at 37°C/5% CO 2 . After a further 18-24 h an additional 5 ml of RPMI + 20% FCS + 1 mm sodium pyruvate containing either 20 g/ml Blasticidin S or 10 g/ml Puromycin was carefully added, resulting in a soft agar selection concentration of 10 and 5 g/ml, respectively. The dishes were returned to culture for a further 2-3 weeks after which soft agar colony number was determined. The concentration in c.f.u./ml was calculated as the number of colonies per dish per well multiplied by the dilution factor. In all c.f.u./ml determinations multiple dilutions were initiated although most would be non-informative, having either too few colonies or too many to count accurately (ie more than 300/60 mm dish). Adherent HeLa cells were trypsinized, counted and adjusted 1 × 10 5 /ml in RPMI + 10% FCS and then plated in 24-well cell culture plates in aliquots of 0.5 ml. After 18 h incubation (37°C/5% CO 2 ) and 1-3 h before infection an additional 0.5 ml of medium containing polybrene was added to bring the final concentration to 4.4 g/ml.
Retrovirus was subjected to serial 1:10 dilutions in RPMI + 10% FCS and triplicate 100 l aliquots of the appropriate dilution added to, and mixed with, the target cells. After 48 h infection, the medium was replaced with fresh medium containing 10 g/ml Blasticidin S. The medium was replaced every 3-4 days for 2 weeks after which it was aspirated, the plates stained with 2 ml Commasie blue stain (5.35% wt/vol in 45% methanol:10% acetic acid), washed in tap water, colonies counted, and the titre determined.
